Clinical Trial Update: Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult. [Phase 1]

View source ↗

Summary

A Phase 1 study assessing the safety and immunogenicity of HIV-1 chimpanzee adenovirus vaccines expressing clade C gp140 with a CH505TF gp120 protein boost in H…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• CH505TF gp120 protein boost (recombinant CH505TF gp120 protein boost)
• HIV-1 chimpanzee adenovirus vaccine expressing clade C gp140 (chimpanzee adenovirus-vectored HIV vaccine expressing clade C gp140)

Snippet

Sponsor: HIV Vaccine Trials Network | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2024-11-27